JPMorgan Chase & Co. Reiterates “Underweight” Rating for Haleon (LON:HLN)

Haleon (LON:HLN)‘s stock had its “underweight” rating reissued by analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Friday, MarketBeat Ratings reports.

HLN has been the topic of a number of other research reports. Berenberg Bank lowered their target price on shares of Haleon from GBX 503 to GBX 500 and set a “buy” rating on the stock in a report on Friday, August 8th. The Goldman Sachs Group reissued a “buy” rating and set a GBX 440 target price on shares of Haleon in a report on Wednesday, September 10th. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a GBX 370 price target on shares of Haleon in a report on Friday. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Haleon currently has a consensus rating of “Hold” and an average target price of GBX 436.67.

Haleon Trading Up 1.4%

Shares of HLN stock opened at GBX 355.70 on Friday. The company’s fifty day simple moving average is GBX 347.67 and its two-hundred day simple moving average is GBX 369.60. The company has a debt-to-equity ratio of 53.36, a current ratio of 0.84 and a quick ratio of 0.93. Haleon has a 1 year low of GBX 325.10 and a 1 year high of GBX 419.50. The stock has a market capitalization of £31.68 billion, a price-to-earnings ratio of 21.30, a PEG ratio of 1.49 and a beta of 0.19.

Haleon (LON:HLN) last issued its earnings results on Thursday, July 31st. The company reported GBX 8.90 earnings per share (EPS) for the quarter. Haleon had a net margin of 9.66% and a return on equity of 6.54%. As a group, analysts anticipate that Haleon will post 19.5033282 earnings per share for the current year.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other.